Radiochemicals for research and clinical use
BV Cyclotron VU is a global health science company that produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Located at the campus of VU University Medical Center in Amsterdam, Cyclotron VU produces GMP- compliant medical isotopes in state-of-the-art manufacturing facilities.
These products are used daily by pharmaceutical and biotechnology companies, medical device manufacturers, hospitals, clinics, and research laboratories.
More information on Zirconium-89 for radiolabeling, Iodine-124 for radiolabeling, Sodium Iodide 124I for injection, 18F-Fludeoxyglucose, 18F-Fluoromethylcholine, 18F-Florbetaben (Neuraceq), KryptoScanTM: 81Rb/81mKr Generator and Type A Transport Container: Lead and Tungsten.
Do you need precise details about when and where to order your product? See our production schedule here.
Also check out our free online decay calculator!
2/2/2017: Newly published research has assessed the radiolabeling of WBCs with 89Zr or 64Cu and their advantages for PET imaging. Radiolabeling of WBCs was more efficient with [89Zr]-loaded than with [64Cu]-loaded CN. After 2 h, [89Zr]-WBCs had an initial radioactivity loss of 28.4%, which was followed by a plateau as 89Zr remains stable in the cells. Differently, [64Cu]-WBCs had a radioactivity loss of 85% already after 1 h, which increased to 96% after 3 h.
Alternative chelator for 89Zr-immuno-PET studies shows superior in vitro stability and in vivo performance
18/1/2017: 89Zr-DFO*-trastuzumab shows to be far superior to 89Zr-DFO-trastuzumab. Recent research has introduced a bifunctional isothiocyanate variant of the octadentate chelator DFO* as an alternative for DFO in 89Zr-immuno-PET. The effects of both molecules, when conjugated with the monoclonal antibody trastuzumab, were compared in vitro (stability tests) and in vivo (biodistribution in N87 tumor-bearing mice and PET imaging).
2/1/2017: 89Zr shows excellent in vitro and vivo behaviour, making it a good alternative for longitudinal PET studies of fungal infections. In an interesting publication, the in vitro, in vivo and ex vivo behavior of selected siderophores labeled with 68Ga and 89Zr have been compared, considering that the latter might constitute a radioisotope-labeling alternative for imaging of infection.
12/9/2016: Research from the university of Duisburg shows high level of agreement between 124I-PET and 131I-imaging. The authors conclude that pre-therapeutic 124I-PET/CT is a suitable procedure to detect iodine-positive metastases in patients with differentiated Thyroid Carcinoma. Moreover, it can be employed as a reliable tool for both staging of thyroid cancer patients as well as individualized treatment planning.